Proactive Investors AustraliaCellmid awarded Japanese patent for autoimmune disorder treatment with …Proactive Investors AustraliaThis adds to its patent coverage and follows its receiving earlier this month of a European patent for the use of anti-m…
|
Rituximab offered little therapeutic benefit in Graves’ ophthalmopathy
Healio SAN JUAN, Puerto Rico — In a randomized, double blind, placebo-controlled trial, rituximab did not effect significant clinical improvement in Graves’ ophthalmopathy and had a 50% success/failure rate in patients with the disease. “In patients with … |
Toronto StarAntibody Treatment Found to Halt Deadly Ebola Virus in PrimatesScientific AmericanBut in a new study, Canadian researchers found that a combination treatment of antibodies and virus-fighting proteins prevented death from Ebola-Zaire in some…
|
Rituximab No Help in Graves’ Eye Disease
MedPage Today Ronald Koenig, MD, PhD, of the University of Michigan in Ann Arbor, who was not involved in the study, said that although the result is “disappointing, it is a very important finding since there is so much need for an effective therapy, and rituximab … Rituximab offered little therapeutic benefit in Graves’ ophthalmopathyHealio |
Wooed by State Spending, Russian Drugmaker Bets on BrazilThe Moscow TimesThe Biocad facility will produce the cancer-fighting trastuzumab, as well as pegylated interferon against rheumatoid arthritis, and rituximab to combat hepatitis type C. Last year…
|
Roche cancer drugs drive healthy sales rise
PharmaTimes The top-selling drug was MabThera/Rituxan (rituximab), approved for non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arthritis, contributed 1.80 billion francs in the oncology setting, an increase of 12%. Sales of … |
Most US adolescents lack antibodies that may help protect against genital …News-Medical.netA new study suggests a growing number of U.S. adolescents lack antibodies that may help protect them later in life against an increasingly important cause of g…
|
David Schenkein, Cancer Doc Turned CEO, Aims to Build New Genentech
Xconomy He was recruited later to oversee the clinical development and regulatory work for several of South San Francisco, CA-based Genentech’s big cancer therapies like bevacizumab (Avastin), trastuzumab (Herceptin), and rituximab (Rituxan). Then, in May 2009 … |
|
15 neue Wirkstoffe angekündigt
Ärzte Zeitung in Phase II ein Alpha-7-Nikotin-Rezeptoragonist (ABT-126) gegen Alzheimer und Schizophrenie getestet, sowie. • zusammen mit einem Partnerunternehmen in Phase III der immunsuppressiv wirkenden Antikörper Daclizumab gegen Multiple Sklerose. |
Rituximab plus epratuzumab effective in follicular lymphomaHealioThe combination of rituximab and epratuzumab was associated with comparable response rates and time to progression as rituximab plus chemotherapy in a cohort of patients with previously u…